Leading the Future of Cholangiocarcinoma Care—Because No One Else Will
Landmark Event: Leading experts & patient advocates united for the largest-ever event on cholangiocarcinoma treatment standardisation in Australia, driving innovation & action.
Catie Brown
Malua Bay mum Jill Brown’s mission to educate Australia on rare cancer that killed ‘beautiful’ daughter Catie. Jill Brown tragically lost her “beautiful” daughter Catie Brown in early 2023, after a hard fought six month battle with cholangiocarcinoma, a rare bile duct cancer.
Understanding Bilirubin: Your Body’s Natural Blood Compost
Learn about bilirubin, its role in your body, symptoms like jaundice and itching, and how to track and respond to changes that impact liver and bile health.
TAS-120: Futibatinib in Advanced Cholangiocarcinoma with FGFR2 Fusions
TAS-120 (Futibatinib) offers hope for advanced cholangiocarcinoma with FGFR2 fusions. Explore the groundbreaking FOENIX-CCA4 Phase 2 study results.
Orphan Drug for Intrahepatic Bile Duct Cancer
Discover how PLT012, an innovative anti-CD36 antibody, targets liver cancer's sneaky recruitment stations, starving tumours, dismantling defences, and empowering T-cells to attack.
World-First Pilot Study Explores New Cholangiocarcinoma Treatment
Join a world-first pilot study testing durvalumab and olaparib for advanced cholangiocarcinoma. Now recruiting at eight sites across Australia. Learn more.
Leading the Future of Cholangiocarcinoma Care—Because No One Else Will
Landmark Event: Leading experts & patient advocates united for the largest-ever event on cholangiocarcinoma treatment standardisation in Australia, driving innovation & action.
Catie Brown
Malua Bay mum Jill Brown’s mission to educate Australia on rare cancer that killed ‘beautiful’ daughter Catie. Jill Brown tragically lost her “beautiful” daughter Catie Brown in early 2023, after a hard fought six month battle with cholangiocarcinoma, a rare bile duct cancer.
Understanding Bilirubin: Your Body’s Natural Blood Compost
Learn about bilirubin, its role in your body, symptoms like jaundice and itching, and how to track and respond to changes that impact liver and bile health.
TAS-120: Futibatinib in Advanced Cholangiocarcinoma with FGFR2 Fusions
TAS-120 (Futibatinib) offers hope for advanced cholangiocarcinoma with FGFR2 fusions. Explore the groundbreaking FOENIX-CCA4 Phase 2 study results.
Orphan Drug for Intrahepatic Bile Duct Cancer
Discover how PLT012, an innovative anti-CD36 antibody, targets liver cancer's sneaky recruitment stations, starving tumours, dismantling defences, and empowering T-cells to attack.
World-First Pilot Study Explores New Cholangiocarcinoma Treatment
Join a world-first pilot study testing durvalumab and olaparib for advanced cholangiocarcinoma. Now recruiting at eight sites across Australia. Learn more.
